Dupilumab as add-on Therapy for Aspirin-exacerbated Respiratory Disease (AERD)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2019
Price : $35 *
At a glance
- Drugs Dupilumab (Primary)
- Indications Asthma; Nasal polyps; Rhinosinusitis
- Focus Therapeutic Use
- 31 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Sep 2018 Status changed from not yet recruiting to recruiting.
- 30 Jul 2018 New trial record